SHANGHAI, Dec. 13, 2015
/PRNewswire/ -- WuXi PharmaTech (Cayman) Inc., a leading
open-access R&D capability and technology
platform company serving the pharmaceutical, biotechnology and
medical device industries, with operations in China and the United
States, announced the winners of the ninth annual
WuXi PharmaTech Life Science and Chemistry Awards at a
ceremony held on December 13 at Diaoyutai State
Guesthouse in Beijing.
Originated in 2007, the WuXi PharmaTech Life Science and
Chemistry Awards are the first nationwide scientific awards in
China established by a life
science enterprise. The awards aim to stimulate early-stage
innovation and to promote excellence in life science and
clinical research. Participants were carefully selected
by a committee comprised of distinguished experts from Chinese life
science academia and industry.
"Congratulations to all of the award winners for their
exceptional scientific accomplishments," said Dr. Ge Li, Chairman and Chief Executive Officer of
WuXi PharmaTech. "WuXi is delighted to present this award to
recognize these bright scholars in China whose research can help our global
industry to better understand diseases and find more effective
cures."
Since its inception, 146 scholars from more
than 30 premier Chinese universities and research
institutes have received WuXi PharmaTech Life Science and Chemistry
Awards, of whom eleven were later elected to the Chinese
Academy of Sciences or the Chinese Academy of
Engineering.
Winners of the 2015 Outstanding Achievements Awards
included:
- Prof. Yihan Chen, Medical
College of Tongji University
- Prof. Feng Zhang, College of
Life Science, Fudan University
- Prof. Jiafu Ji, Beijing Cancer
Hospital
Winners of the 2015 Scholar Awards included:
- Prof. Yingyan Yu, Rui Jin Hospital, Shanghai Jiao Tong
University School of Medicine
- Prof. Zhanju Liu, Shanghai Tenth People's Hospital
- Prof. Zuguo Liu, Medical College of Xiamen University
- Dr. Ang Li, Shanghai Institute
of Organic Chemistry, Chinese Academy of Sciences
- Dr. Junmin Li, Rui Jin Hospital,
Shanghai Jiao Tong University School of Medicine
- Prof. Qiurong Li, Nanjing
General Hospital of Nanjing Military Command
- Prof. Haitao Li, Medical College
of Tsinghua University
- Prof. Peifeng Li, Institute for
Translational Medicine, Qingdao
University
- Prof. Luoting Yu, State Key Laboratory of Biotherapy,
Sichuan University
- Prof. Xue Zhang, Institute of
Basic Medical Sciences, Chinese Academy of Medical Sciences
- Prof. Zijiang Chen, Medical
College of Shandong
University
- Prof. Rongbin Zhou, College of Life Sciences, University
of Science and Technology of China
- Prof. Jingpin Zhen, First Affiliated Hospital of Guangzhou
Medical University
- Dr. Yanhui Xu, Biomedical
Research Institute of Fudan University
- Dr. Xuefeng Guo, College of
Chemistry and Molecular Engineering, Peking University
About WuXi PharmaTech
WuXi PharmaTech is a leading open-access R&D capability and
technology platform company serving the pharmaceutical,
biotechnology, and medical device industries, with operations in
China and the United States.
As a research-driven and customer-focused company, WuXi PharmaTech
provides a broad and integrated portfolio of services throughout
the drug and medical device R&D process. WuXi is also
building a platform to provide clinical diagnostic services
directly to physicians and their patients globally. WuXi
PharmaTech's services are designed to assist its global partners in
shortening the cycle and lowering the cost of drug and medical
device R&D. WuXi PharmaTech's operating subsidiaries are known
as WuXi AppTec. For more information, please visit
http://www.wuxiapptec.com.
For more information, please contact:
Ronald Aldridge (for
investors)
LaVoieHealthScience
+1 952-594-0148
ron_aldridge@wuxiapptec.com
Aaron Shi (for media)
Director, Corporate Communications
WuXi PharmaTech
+86-21-5046-4362
aaron_shi@wuxiapptec.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/wuxi-pharmatech-presents-2015-life-science-and-chemistry-awards-300192138.html
SOURCE WuXi PharmaTech (Cayman) Inc.